Bard Touts Devices To Treat Unsuccessful Gastric Bypass And Atrial Fib
This article was originally published in The Gray Sheet
Executive Summary
Bard's endovascular suturing technology could prove useful in salvaging unsuccessful Roux-en-Y gastric bypass surgeries, the company says
You may also be interested in...
Preliminary Study Backs Radiofrequency Ablation As Primary AF Treatment
Treatment of symptomatic atrial fibrillation using pulmonary vein isolation (PVI) with radiofrequency ablation could prove safe and effective as a first-line alternative to antiarrthymic drugs, a pilot study published June 1 in the Journal of the American Medical Association suggests
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.